CSL’s ANDEMBRY® Gains FDA Approval for Hereditary Angioedema Treatment

The latest announcement is out from CSL ( (AU:CSL) ).

CSL has announced the FDA approval of ANDEMBRY®, a groundbreaking treatment for hereditary angioedema (HAE), marking its immediate launch in the United States. This approval enhances CSL’s market positioning, offering the first and only prophylactic treatment targeting factor XIIa for HAE, with significant efficacy demonstrated in clinical trials. The treatment’s approval in multiple regions, including the EU and Japan, underscores its global impact and potential benefits for patients, stakeholders, and the company’s operations.

The most recent analyst rating on (AU:CSL) stock is a Buy with a A$325.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.

More about CSL

CSL is a global biotechnology company based in Melbourne, Australia, specializing in the development and delivery of innovative medicines and therapies. The company focuses on treating rare and serious diseases, with a strong emphasis on immunology and hematology.

YTD Price Performance: -14.49%

Average Trading Volume: 893,127

Technical Sentiment Signal: Sell

Current Market Cap: A$115.7B

See more insights into CSL stock on TipRanks’ Stock Analysis page.